SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Trzeciak Magdalena) "

Sökning: WFRF:(Trzeciak Magdalena)

  • Resultat 1-2 av 2
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Szczesna-Chrzan, Anna, et al. (författare)
  • Systematic Studies on Liquid Sodium 4,5-dicyano-2-(trifluoromethyl)imidazolate (NaTDI)-Based Electrolytes and Its Impact on the Cycling Behaviour Against Wet Impregnated WI-NaNMC and Prussian White Cathodes
  • 2022
  • Ingår i: Advanced Materials Interfaces. - : John Wiley & Sons. - 2196-7350. ; 9:8
  • Tidskriftsartikel (refereegranskat)abstract
    • The article describes a research on new salts and cathode materials dedicated to sodium cells. Sodium technology is considered to be one of the most promising (for new battery generations) and has been very actively (re)-developed for more than a decade. The first part of this work is mainly focused on electrochemical studies of the low coordinating Huckel type salt (4,5-dicyano-2-(trifluoromethyl)imidazolate, NaTDI)-based electrolytes with and without solid electrolyte interface modified additives: fluoroethylene carbonate (FEC). In the second part electrolytes are tested in a half-cells with layered oxides. Sodium nickel-manganese-cobalt oxide (NaNMC) and WI-NaNMC-333 and WI-NaNMC-622 layered cathode materials are prepared by wet impregnation synthesis (WI) routine. Prussian White is obtained from University of Uppsala group to compare and initial electrochemical properties against electrolyte with NaTDI. Basic physicochemical properties of the obtained powders are also reported in the manuscript. The best properties are recorded for 0.75 m NaTDI in EC:DMC (1:1 v/v) with 3% FEC additive by its conductivity (11.52 mS cm(-1) for 20 degrees C). The same solution also shows promising results during electrochemical tests in half-cell geometry against WI-NaNMC-622 cathode (114.22 mAh g(-1) after 1 cycle C/20). NaPF6 salt is used as an electrolyte as a commercially available reference.
  •  
2.
  • Wollenberg, Andreas, et al. (författare)
  • European Task Force on Atopic Dermatitis (ETFAD) statement on severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2)-infection and atopic dermatitis
  • 2020
  • Ingår i: Journal of the European Academy of Dermatology and Venereology : JEADV. - : Wiley. - 1468-3083 .- 0926-9959. ; 34:6, s. 241-242
  • Tidskriftsartikel (refereegranskat)abstract
    • Atopic dermatitis (AD) is a complex disease with elevated risk of respiratory comorbidities.1,2 Severely affected patients are often treated with immune-modulating systemic drugs.3,4 On March 11th 2020, the World Health Organization declared the 2019 novel coronavirus severe acute respiratory syndrome (SARS-Cov-2) epidemic to be a pandemic. The number of cases worldwide is increasing exponentially and poses a major health threat, especially for those who are elderly, immuno-compromised, or have comorbidities. This also applies to AD patients on systemic immune-modulating treatment. In these days of uncertainty, reallocation of medical resources, curfew, hoarding, and shutdown of normal social life, patients, caregivers and doctors ask questions regarding the continuation of systemic immune-modulating treatment of AD patients. The ETFAD decided to address some of these questions here.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-2 av 2

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy